Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    Menu

    Amiselimod

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bausch Health Reports R&D Updates Amiselimod Data At Conferences
    Bausch Health Reports R&D Updates Amiselimod Data At Conferences

    14 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=877482&lang=en

    ACCESSWIRE
    14 Jun 2024
    Share Share
    Salix Presents Phase 2 Amiselimod UC Data At DDW 2024
    Salix Presents Phase 2 Amiselimod UC Data At DDW 2024

    17 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/864258/salix-to-present-late-breaking-data-from-phase-2-trial-of-amiselimod-in-active-ulcerative-colitis-at-digestive-disease-week-2024

    ACCESSWIRE
    17 May 2024
    Share Share
    Bausch Announces Positive Results From Phase 2 Study Evaluating Amiselimod
    Bausch Announces Positive Results From Phase 2 Study Evaluating Amiselimod

    21 Dec 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=819070&lang=en

    ACCESSWIRE
    21 Dec 2023
    Share Share